Literature DB >> 7784345

Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats.

L H Wang1, R M Fielding, P C Smith, L S Guo.   

Abstract

The pharmacokinetic profiles of amphotericin B (AmB) after administration of Amphocil, an AmB/cholesteryl sulfate colloidal dispersion (ABCD) and the micellar AmB/deoxycholate (Fungizone) were compared after repeated dosing in rats. After administration of ABCD and Fungizone at an equal AmB dose (1 mg/kg), AmB concentrations in plasma and most tissues were lower for the ABCD dose, especially in the kidneys where reduced drug concentration correlated with reduced nephrotoxicity. In contrast, AmB concentrations in the liver were substantially higher when ABCD was administered; however, without an accompanying increase in hepatotoxicity. Daily administration of ABCD for 14 days did not lead to AmB accumulation in plasma; while a slight accumulation was observed after multiple administration of Fungizone. AmB was eliminated more slowly from the plasma and various tissues and urinary and fecal recoveries of AmB were reduced after ABCD administration. These results suggest that ABCD may be stored in tissues in a form that is less toxic and is eliminated from the systemic circulation by a different mechanism than the free and protein-bound AmB in plasma. AmB accumulation in the spleen was observed when higher, doses of ABCD (5 mg/kg) were administered, which could be due to saturation of hepatic uptake of AmB. Comparison of spleen concentrations of AmB between ABCD and Fungizone at 5 mg/kg AmB doses was not possible because of Fungizone's toxicity in rats. In all other organs, AmB concentrations reached or approached a steady state within two weeks of dosing with ABCD. Urinary and fecal clearences of AmB were not different between ABCD and Fungizone administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784345     DOI: 10.1023/a:1016243313027

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Hypocholesterolemic effect of amphotericin B: an analytical approach.

Authors:  A C Parekh; R J Creno; C V Dave
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-10

2.  Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

Authors:  H Kim; D Loebenberg; A Marco; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 3.  Antioxidant-stabilized amphotericin B.

Authors:  W H Beggs
Journal:  Diagn Microbiol Infect Dis       Date:  1983-12       Impact factor: 2.803

4.  Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.

Authors:  R M Fielding; A W Singer; L H Wang; S Babbar; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Amphotericin B in liposomes: a novel therapy for histoplasmosis.

Authors:  R L Taylor; D M Williams; P C Craven; J R Graybill; D J Drutz; W E Magee
Journal:  Am Rev Respir Dis       Date:  1982-05

6.  Solubility and stability of amphotericin B in human serum.

Authors:  L C Edmonds; L Davidson; J S Bertino
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

7.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

8.  High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies.

Authors:  L H Wang; P C Smith; K L Anderson; R M Fielding
Journal:  J Chromatogr       Date:  1992-09-02

Review 9.  The role of liposomal amphotericin B in the treatment of systemic fungal infections.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Cancer Clin Oncol       Date:  1989

10.  Excretion pathways of amphotericin B.

Authors:  P C Craven; T M Ludden; D J Drutz; W Rogers; K A Haegele; H B Skrdlant
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

View more
  11 in total

1.  Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

Authors:  A H Groll; D Mickiene; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Authors:  I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.

Authors:  Leonid Kagan; Pavel Gershkovich; Kishor M Wasan; Donald E Mager
Journal:  Pharm Res       Date:  2013-06-21       Impact factor: 4.200

5.  Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.

Authors:  S Saxena; P C Ghosh
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Authors:  Andreas H Groll; Caron A Lyman; Vidmantas Petraitis; Ruta Petraitiene; Derek Armstrong; Diana Mickiene; Raul M Alfaro; Robert L Schaufele; Tin Sein; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

7.  Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.

Authors:  Leonid Kagan; Pavel Gershkovich; Kishor M Wasan; Donald E Mager
Journal:  AAPS J       Date:  2011-03-23       Impact factor: 4.009

8.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.